Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

Background: The addition of bevacizumab to chemotherapy improves progression-free survival in metastatic breast cancer and pathological complete response rates in the neoadjuvant setting. Micrometastases are dependent on angiogenesis, suggesting that patients might benefit from anti-angiogenic strat...

Full description

Bibliographic Details
Main Authors: Cameron, David, Brown, Julia, Dent, Rebecca, Jackisch, Christian, Mackey, John, Pivot, Xavier, Steger, Guenther, Suter, Thomas, Toi, Masakazu, Parmar, Mahesh, Laeufle, Rita, Im, Young-Hyuck, Romieu, Gilles, Harvey, Vernon, Lipatov, Oleg, Pienkowski, Tadeusz, Cottu, Paul, Chan, Arlene, Im, Seock-Ah, Hall, Peter, Bubuteishvili-Pacaud, Lida, Henschel, Volkmar, Deurlog, Regula, Pallaud, Celine, Bell, Richard
Format: Journal Article
Published: The Lancet Publishing Group 2013
Online Access:http://hdl.handle.net/20.500.11937/9768

Internet

http://hdl.handle.net/20.500.11937/9768

Similar Items